Form 4: Eloxx Pharmaceuticals Director Receives Stock Options

Director Steven D. Rubin was granted 4,018 stock options in Eloxx Pharmaceuticals, Inc. as part of a compensation arrangement.

Summary

• Director Steven D. Rubin received a grant of 4,018 stock options on June 8, 2026.
• The options have an exercise price of $11.00 per share.
• The options vest in 24 equal monthly installments, becoming fully vested on June 8, 2028.
• The options expire on June 8, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that does not signal a change in company fundamentals.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is contingent upon the director's continuous service to the issuer.

Future Outlook

The options vest over a 24-month period, indicating a long-term retention incentive for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The use of monthly vesting over two years is consistent with standard director compensation packages for small-cap pharmaceutical companies.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Director to continue service to satisfy vesting requirements.

Key Dates

Keywords

Eloxx Pharmaceuticals, ELOX, Form 4, Insider Trading, Stock Options, Director Compensation